PALI Palisade Bio, Inc.
Company Updates ·
The company reported a net loss of $10.6 million for the quarter and cash of $125.2 million at June 30, 2026. It expects to start the Phase 2 ASCENTRA-UC trial in the second half of 2026.
The annual meeting on June 10, 2026 approved raising authorized common stock from 300,000,000 to 450,000,000 shares. Stockholders also approved two amended equity plans.
The company reported cash and cash equivalents of $132.6 million at March 31, 2026. It said the Phase 2 ulcerative colitis trial of PALI-2108 is expected to start in the third quarter of 2026.
The company sold 1,536,885 shares at $1.952 per share, with the sale closing on March 27, 2026. It also signed an agreement with Iterative Health to help enroll patients in its planned Phase 2 ulcerative colitis study.
A holder will exercise 4,318,905 Palisade warrants at a reduced price and receive new warrants for up to 8,637,810 shares. Ladenburg Thalmann is the placement agent.
Palisade Bio received a Nasdaq minimum bid price notice on April 30, 2025, after its stock closed below $1.00 for 30 consecutive trading days. It has 180 calendar days to regain compliance, and its 2024 annual report carries a going-concern warning alongside $9.8 million of cash.
Palisade Bio has 180 calendar days from an April 30, 2025 Nasdaq notice to get its shares back above $1.00, and its lead candidate is still in a Phase 1 study.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $16.0 million | |
| Net income (loss) | -$16.8 million | -$14.4 million |
| Cash from operations | -$10.8 million | -$12.2 million |
| Cash and equivalents | $133.4 million | $9.8 million |
Our latest story on this, dated May 2, 2025: "Palisade Bio gets Nasdaq minimum bid price deficiency notice, has 180 days to regain compliance". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Mar 27, 2026: "Palisade Bio sells $3.0 million of stock to an affiliate of Iterative Health". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated May 2, 2025: "Palisade Bio gets Nasdaq minimum bid price deficiency notice, has 180 days to regain compliance". The story links the filing or release it is based on. Read the story.
Palisade Bio, Inc. trades under the ticker PALI on NASDAQ.
Palisade Bio, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Palisade Bio, Inc. is 1357459. Its filings are on SEC EDGAR.
174,270,558 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-10.
Our directory records Palisade Bio, Inc. under United States.
Our directory classifies Palisade Bio, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Palisade Bio, Inc. is US6963894026.
aibio.space lists Palisade Bio, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Palisade Bio, Inc. reported a net loss of $16.8 million for the fiscal year ended Dec 31, 2025, and used $10.8 million of cash in operations, per its annual report to the SEC.
$125.2 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on Palisade Bio, dated Aug 10, 2026: "Palisade Bio reports second quarter 2026 results and Phase 2 plans for PALI-2108". The company reported a net loss of $10.6 million for the quarter and cash of $125.2 million at June 30, 2026. It expects to start the Phase 2 ASCENTRA-UC trial in the second half of 2026. Source.
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.03,5.07,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.03,5.07,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Filed a final prospectus for a securities offering. SEC Form S-1. Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio